News Story: Full Text
Sponsored By
Cedars-Siani Medical Center Brain Tumor Program
Please Click On The Above Banner For More Details
Braintumor Website

 

Raven biotechnologies inc., Presenting Data on Its Lead Product at the American Association for Cancer Research (AACR) Annual Meeting


Posted on: 04/18/2005

Raven biotechnologies inc., Presenting Data on Its Lead Product at the American Association for Cancer Research (AACR) Annual Meeting


Data Demonstrates RAV12's Anti-Tumor Activity

SOUTH SAN FRANCISCO, Calif., April 18 /PRNewswire/ -- Raven biotechnologies, inc. announced today the company is presenting preclinical data on RAV12, its lead clinical stage therapeutic monoclonal antibody for GI and other adenocarcinoma related cancers. The data is being presented at the American Association for Cancer Research (AACR) annual meeting April 16-20 in Anaheim, California.

Raven scientists will present the following abstract: "The Monoclonal Antibody RAV12 Induces Oncotic Cell Death in vitro and Exhibits Potent Anti-tumor Activity in Human Tumor Xenografts." (Abstract # 558), D. Loo, et al.

"This data supports the IND application for RAV12 for the treatment of advanced stage adenocarcinomas which we filed last November," said Jennie Mather, PhD, President and CEO of Raven. "The data presented at AACR provides further support for the potential of RAV12 for the treatment of GI cancers and validates the power of our discovery platform, which is focused exclusively on therapeutic antibodies for cancer." The IND application was accepted by the FDA and Raven commenced its phase 1 clinical in December 2004.

About Raven

Raven biotechnologies, inc. (http://www.ravenbio.com) is a privately held biotechnology company initially focused on the development of monoclonal antibodies therapeutics for treating cancer. Raven's lead product candidate, RAV12, targets adenocarcinomas of the GI tract and is in an on-going phase 1 clinical trial. Raven's proprietary discovery process simultaneously identifies novel cell-surface drug targets and the antibody therapeutics to regulate them. Raven's integrated approach is based on proprietary, human tissue-specific progenitor and tumor stem cell lines developed at Raven, plus proprietary methods optimized for producing MAbs targeting cell-surface proteins. This platform rapidly identifies target antigens and therapeutic candidates in their native configuration in the intact cell membrane. The Company has identified candidate therapeutic MAbs for many cancer indications including lung, colon, pancreatic, prostate, breast, brain, and ovarian cancer.
SOURCE Raven biotechnologies, inc.
Web Site: http://www.ravenbio.com


Click HERE to return to brain tumor news headlines


Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2019 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557
888-295-4740